AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:INNTInnovate Biopharmaceuticals Stock Price, Forecast & News

$0.60
+0.02 (+3.45 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.56
Now: $0.60
$0.62
50-Day Range
$0.44
MA: $0.55
$0.74
52-Week Range
$0.37
Now: $0.60
$1.67
Volume285,800 shs
Average Volume525,982 shs
Market Capitalization$24.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.39
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Read More
Innovate Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Employees8
Market Cap$24.79 million
Next Earnings DateN/A
OptionableOptionable

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INNT shares have increased by 27.2% and is now trading at $0.5999. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Innovate Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovate Biopharmaceuticals.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

Press coverage about INNT stock has trended somewhat negative on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutInnovate Biopharmaceuticals.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), Axsome Therapeutics (AXSM), Alibaba Group (BABA), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Avid Bioservices (CDMO).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.60.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $24.79 million. Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.